Key facts
- Neuronoff has implanted the first patient in a clinical trial.
- The trial is funded by the Department of Defense.
- The trial is testing the Injectrode® device for neurogenic bladder in spinal cord injury patients.
- The Injectrode® is a needle-delivered electrode.
- The device enables outpatient placement and at-home stimulation.
Neuronoff, Inc., a clinical-stage neuromodulation company, has announced the successful implantation of the first patient in a clinical trial for its Injectrode® device. This trial, funded by the Department of Defense, aims to evaluate the Injectrode®'s efficacy in treating neurogenic bladder, a condition often experienced by individuals with spinal cord injuries. The Injectrode® is designed as a needle-delivered electrode, allowing for a less invasive outpatient placement procedure. Furthermore, the device is intended to enable patients to perform at-home stimulation, offering a more convenient and accessible treatment option for managing neurogenic bladder.